<DOC>
	<DOC>NCT02871622</DOC>
	<brief_summary>Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data collection. Major adverse cardiac events (MACE) results at 9 months will be compared to the results obtained from the BioMatrix FlexTM arm of the LEADERS trial.</brief_summary>
	<brief_title>BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina, Stable</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>Patients treated with the BioMatrix AlphaTM stent per clinical indication and physician's choice; Patients who agree to comply with the follow up requirements; Patients with a life expectancy of &gt; 1 year at time of consent; Patients eligible to receive dual anti platelet therapy (DAPT) according to guidelines; Hemodynamically stable patients. Inability to provide informed consent; Currently participating in another trial before reaching primary endpoint; Planned surgery within 6 months of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the perisurgical period; Patient has received an additional stent different from a BioMatrix AlphaTM stent during the index procedure.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>